Ocular Hypertension Clinical Trial
Official title:
Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging
Verified date | August 2019 |
Source | Medical University of Vienna |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Glaucoma is among the leading causes for blindness in the western world. Elevated intraocular
pressure (IOP) has been identified as the most important risk factor. However, some patients
progress despite adequate IOP lowering while some subjects with elevated IOP never develop
glaucoma. Other patients develop glaucoma although IOP measurements were always in the normal
range. Therefore, other factors must be involved. In the last years, studies using MRI have
been performed and evidence has accumulated that also changes in retrobulbar structures are
present, in particular in the lateral geniculate nucleus and the visual cortex. However,
these studies were limited by the low spatial resolution of the MRI instruments used.
The investigators propose to overcome this problem by using an ultrahigh-field Magnetom 7T
whole-body MR scanner (Siemens Medical, Germany) installed at the MR Centre of Excellence at
the Medical University of Vienna. This scanner is equipped with a 32-channel head coil and
the SC72 high-performance gradient system and is thus perfectly suited for structural and
functional imaging. The aim of the present study is to investigate whether structural and
functional parameters are altered in patients with primary open angle glaucoma (POAG), normal
tension glaucoma (NTG), ocular hypertension (OHT) compared to healthy control subjects. The
exact topographical survey of intracranial structures such as the LGN and the assessment of
neuronal structures by DTI may allow for the better assessment of therapeutic responses to
new neuroprotective agents.
Status | Terminated |
Enrollment | 120 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Healthy controls - Men and women aged over 18 years - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings Patients with ocular hypertension - Men and women aged over 18 years - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Normal ophthalmic findings except presence of ocular hypertension (defined as untreated IOP = 21 mmHg on at least three measurements in the medical history, no signs of glaucomatous damage in the optic disc or the glaucoma hemifield test) Patients with primary open angle glaucoma - Men and women aged over 18 years - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Diagnosis of manifest primary open angle glaucoma (defined as pathological optic disc appearance, glaucoma hemifield test outside normal limits and untreated IOP > 20 mmHg on at least three measurements in the medical history) - Mean Deviation in the visual field test = 10dB Patients with normal-tension glaucoma - Men and women aged over 18 years - Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant - Diagnosis of normal-tension glaucoma (defined as pathological optic disc appearance, glaucoma hemifield test outside normal limits and untreated IOP = 20 mmHg on at least three measurements in the medical history) - Mean Deviation in the visual field test = 10dB Exclusion Criteria: - Symptoms of a clinically relevant illness in the 3 weeks before the first study day - Presence or history of a severe medical condition as judged by the clinical investigator - Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study - Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure - Intraocular surgery within the last 6 months - Ocular inflammation or infection within the last 3 months - Pregnancy, planned pregnancy or lactating - Any metallic, electric, electronic or magnetic device or object not removable except dental fillings - Claustrophobia |
Country | Name | City | State |
---|---|---|---|
Austria | Department of Clinical Pharmacology | Vienna |
Lead Sponsor | Collaborator |
---|---|
Medical University of Vienna |
Austria,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | High resolution functional and structural imaging of the visual pathway | The visual pathway will be imaged with 7-Tesla MRI. The images will be compared between the study groups. | once on the study day (approximately 1 hour) | |
Secondary | Retinal nerve fiber thickness | Parameters obtained from GDX and OCT measurements will be compared between groups. | once on the study day (approximately 10 minutes) | |
Secondary | Visual field test | Parameters from the Humphrey visual field test will be used for classification of severity of glaucoma or to prove that subjects are healthy. | once on the study day (approximately 20 minutes) | |
Secondary | Intraocular Pressure | Goldmann applanation tonometry will be used for measurement of intraocular pressure. | once on the study day (1 minute) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03284853 -
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT01157364 -
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06441643 -
Next Generation Rocklatan
|
Phase 2 | |
Recruiting |
NCT02792803 -
A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma
|
Phase 4 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Terminated |
NCT02801617 -
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02558374 -
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02338362 -
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
|
Phase 4 | |
Completed |
NCT02993445 -
Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension
|
N/A | |
Completed |
NCT01936389 -
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
|
Phase 2 | |
Completed |
NCT01995136 -
Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Completed |
NCT02003547 -
A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01664039 -
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®
|
Phase 4 | |
Completed |
NCT01693315 -
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
|
Phase 2 | |
Active, not recruiting |
NCT01430923 -
Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost
|
N/A | |
Completed |
NCT01340014 -
Patient Preference Comparison of AZARGA Versus COSOPT
|
Phase 4 | |
Completed |
NCT01489670 -
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
|
N/A |